Pharmaceutical Technology, Aug 1, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Aug 1, 2012
Articles
CROs and CMOs Have Cause to Celebrate
By Jim Miller
Annual survey shows strong growth for service providers and promises to continue into 2013.
Quality by Design: A Contract Organization's Perspective
By Anil Kane
The author discusses how a CDMO helps in gaining process understanding and in developing robust, high-quality products and processes.
A Manufacturing Capacity-Sharing Model: Merck & Co. and MedImmune LLC
By Patricia Van Arnum
The manufacturing capacity-sharing model in biologics and Merck & Co. and MedImmune ushers in a new paradigm of "co-opetition".
Market Strengths and Weaknesses in Biosimilars
By Patricia Van Arnum
An examination of the current and projected market for biosimilars, development costs for biosimilars compared with small-molecule generic drug, and partnerships in biosimilars.
Strategies in Outsourcing: Insourcing Emerges as an Alternative Model
By Patricia Van Arnum
AMRI, a contract research and manufacturing organization, discusses its adaption of an insourcing model with Eli Lilly.
Strategies in Outsourcing Facilities Management
By Rakesh Kishan , Andrew Cieslak
The authors highlight costs, benefits, and implementation success factors across first, second, and third generations of facility management outsourcing contracts.
Size Associations in the CRO Outsourcing Relationship
By Janice Hutt
The author provides results and commentary on a survey analyzing outsourcing strategies, practices, challenges, and outcomes in the selection of a CRO.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here